Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.39 |
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22791028 | 0.93 | MAOB (0.42) | MAOBMAOAHRH3SLC6A4ALDH1A1 | |
| SCHEMBL25075206 | 0.90 | MAOB (0.38) | MAOBMAOAHRH3SLC6A4ALDH1A1 | |
| SCHEMBL19605014 | 0.88 | MAOB (0.39) | MAOBMAOAHRH3SLC6A4ALDH1A1 | |
| SCHEMBL24847753 | 0.86 | ALDH1A1 (0.45) | HRH3ALDH1A1KDM4EHTT | |
| SCHEMBL25730066 | 0.84 | ALDH1A1 (0.43) | HRH3ALDH1A1KDM4E | |
| SCHEMBL13412957 | 0.84 | MAOB (0.46) | MAOBMAOASLC2A1DAOKDM1A | |
| SCHEMBL21455987 | 0.83 | KDM4E (0.34) | HRH3ALDH1A1KDM4ELMNAHTT | |
| SCHEMBL22848922 | 0.83 | MAPK1 (0.39) | ALDH1A1KDM4EMAPK1KDM1AHTT | |
| SCHEMBL21016113 | 0.83 | HSD11B1 (0.35) | HRH3ALDH1A1KDM4EHTT | |
| SCHEMBL24673304 | 0.83 | HRH3 (0.35) | HRH3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | MAOB 900/4885MAOA 860/4885HRH3 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.